Telavant Holdings (Roivant/Pfizer JV) Deal History & Licensing Activity
Telavant Holdings (Roivant/Pfizer JV) is a life sciences. Over the past three years, Telavant Holdings (Roivant/Pfizer JV) has been involved in 5 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals).
Deals (12mo)
4
Active Trials
0
Top Modality
Antibodies
Focus Area
Mega Deals
Telavant Holdings (Roivant/Pfizer JV) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Telavant Holdings (Roivant/Pfizer JV) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| 12-program antibody-based oncology collaboration | Pfizer | Antibodies | Discovery | collaboration | May 2026 |
| 12-asset antibody-based oncology collaboration | Pfizer | Antibodies | Discovery | collaboration | May 2026 |
| Metsera pipeline | Pfizer | Other | Unknown | acquisition |
Telavant Holdings (Roivant/Pfizer JV) Pipeline Focus
Therapeutic areas and modalities where Telavant Holdings (Roivant/Pfizer JV) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Telavant Holdings (Roivant/Pfizer JV)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Telavant Holdings (Roivant/Pfizer JV) Licensing & Deal Activity
Telavant Holdings (Roivant/Pfizer JV) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Telavant Holdings (Roivant/Pfizer JV) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Telavant Holdings (Roivant/Pfizer JV) include Mega Deals (4 deals and trials), Option Deals (3 deals and trials), and Codev Deals (1 deal and trial). In terms of modality, Telavant Holdings (Roivant/Pfizer JV) has shown particular interest in antibodies, other, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Telavant Holdings (Roivant/Pfizer JV) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Telavant Holdings (Roivant/Pfizer JV)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.